| Objective: To investigate the effect of Bailing Capsule and tripterygium glycosides(TG)on the level of liver-type fatty acid binding protein(L-FABP)in urine of patients with diabetic nephropathy(DN),so as to provide the basis for clinic treatment of DN.Methods: A total of 100 cases of patients with type 2 diabetes combined with nephropathy and admitted to our hospital from October 2016 to October 2017 were selected and included in this study,including 52 male patients and 48 female patients,with the average age of 56.61±8.21,and the average disease course of 110.16±29.84 months.Then enzyme linked immunosorbent assay(ELISA)was used to measure the content of L-FABP in urine of these patients.Meanwhile,the liver and renal functions,the levels of cholesterol(TC),triglyceride,fasting blood glucose(FBG)and glycosylated hemoglobin(HbA1c)and 24-hours urinary albumin excretion rate(UAER)of the patients were measured,and the glomerular filtration rate(eGFR)and other indexes were calculated.The included DN patients were randomly divided into irbesartan group(Group A,n=25),irbesartan combined with Bailing Capsule group(Group B,n=25)),irbesartan combined with TG group(Group C,n=25)),irbesartan combined with Bailing Capsule and TG group(Group D,n=25).Based on blood glucose control,patients in Group A,Group B,Group C and Group D were respectively treated with irbesartan(150mg,qd),irbesartan combined with Bailing Capsule(1.0g,tid),irbesartan combined with TG(20mg,tid)and isodose irbesartan,Bailing Capsule and TG.The change in urine L-FABP level was detected at 12 weeks,and the above-mentioned related clinical evaluation indexes were detected and recorded.The changes in indexes between the four groups before and after treatment were compared and statistical analysis was conducted.In addition,adverse events during follow-up visit were recorded.Results: At the end of the follow-up visit,the urine L-FABP levels of all the patients were decreased compared with the baseline level(P<0.05),the L-FABP levels in Group B,C and D were superior to that in Group A,the L-FABP level in Group C was superior to that in Group B and the L-FABP level in Group D was superior to that in Group C;In Group A,the level of 24 h UAER was lower than baseline level,and there was no statistical difference in other indexes(P>0.05).The level of FPG,HbA1 c,cholesterol and TG in Group B was lower than baseline level and superior to that in Group A(P<0.05).The level of 4h UAER in Group D was lower than baseline level(P<0.05),and superior to that in Group C(P<0.05).Besides,the level of FPG,HbA1 c,TC,and TG was lower than baseline level(P<0.05).There was no statistical difference in the incidence of adverse reactions between the four groups(P>0.05).Conclusion: 1.Both Bailing Capsule and TG can decrease urine L-FABP level of DN patients,and combined usage of the two is superior to single usage;L-FABP may act as an effective indicator for clinic treatment of DN;2.Both Bailing Capsule and TG can reduce urinary protein excretion,the effect of TG is superior to that of Bailing Capsule in terms of reducing urine proteins,and combined usage of the two is superior to single usage;Bailing Capsule can achieve better effect in improving blood glucose and blood fat levels than TG;3.Some of the patients in TG group had liver function damage and gastrointestinal reactions,while patients treated by Bailing Capsule showed no obvious adverse reactions;based on conventional therapy,Bailing Capsule and TG can be combined to treat early-stage DN... |
PDF Full Text Request